急性冠脉综合征患者行介入治疗后应用瑞舒伐他汀的临床价值

目的分析急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后应用瑞舒伐他汀强化治疗的临床价值。方法选择2015年10月~2016年10月期间我院心血管内科和急诊ICU收治的72例ACS患者,并按随机数字法分为对照组和观察组。两组患者入院后均接受,术后并基于常规药物治疗;观察组在常规治疗的基础上增加瑞舒伐他汀的用药。详细记录测量的各数据,对比患者治疗前后的身体各项指标的变化情况,同时详细观察患者的预后情况。结果组内对比,患者的治疗1、3个月后的TG、TC、HDL-C及LDL-C各项血脂指标均优于治疗前;组间对比,观察组治疗后的TG、TC、HDL-C及LDL-C明显优于对照组治疗相同时间后的水平(P0.05)。组内对比,患者的治疗1、3个月后的IL-6、hs-CRP及TNF-α各项炎症因子均低于治疗前;组间对比,观察组的IL-6、hs-CRP及TNF-α各项炎症因子明显低于对照组治疗相同时间后的炎症因子含量(P0.05)。对比两组患者治疗后的预后情况,观察组的心血管事件发生4(11.11%)、再狭窄2(5.56%)明显低于对照组心血管事件发生9(25.00%)、再狭窄5(13.89%)(P0.05)。结论 ACS患者施PCI术后增加瑞舒伐他汀药物的强化治疗,可明显改善患者术后的血脂指标和炎症因子含量,并减少术后心血管事件发生及再狭窄的发生率,提高患者的临床效果,具有临床参考价值。

The Clinical Value of Rosuvastatin for Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention

Objective To analyze the clinical application value of rosuvastatin for patients with acute coronary syndrome (ACS)after percutaneous coronary intervention (PCI).Methods 72 patients with ACS were admitted to our hospital from October 2015 to October 2016 and were randomly divided into the control group and the observation group.Two groups of patients were treated by PCI after operation,and based on the conventional drug treatment;the observation group in the conventional treatment based on the increase of rosuvastatin treatment.The data were recorded in detail,and the changes of body indexes before and after treatment were compared.Results In contrast,patients in the treatment of after 1,3 months the TG,TC,HDL-C and LDL-C blood lipid indexes were better than before treatment;the comparison between the two groups,the observation group TG 、TC 、HDL-C and LDL-C blood lipid index was significantly better than that of the control group of TG、TC、HDL-C and LDL-C after treatment at the same time (P ＜ 0.05).In contrast,patients in the treatment of after 1,3 months the IL-6,hs-CRP and TNF-α of the inflammatory factors were lower than those before treatment;the comparison between the two groups,the observation group IL-6,hs-CRP and TNF-α of the inflammatory factor was significantly lower than that of the control group in the same time after treatment (P ＜ 0.05).The prognosis of the two groups of patients after treatment,the observation group of Cardiovascular events occurred in 4 (11.11％),restenosis of 2 (5.56％) was significantly lower than the control group Cardiovascular eventsoccurred in 9 (25.00％),restenosis of 5 (13.89％) (P ＜ 0.05).Conclusion Application of ACS patients after PCI added rosuvastatin drug treatment,could significantly improve the postoperative blood lipid index and inflammatory cytokines content,and reduced the postoperative incidence of Cardiovascular events and the incidence of restenosis,improved the clinical effect of patients,with clinical reference value.